메뉴 건너뛰기




Volumn 18, Issue 2, 2013, Pages 110-122

Activity-based kinase profiling of approved tyrosine kinase inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LIPID; NILOTINIB; PAZOPANIB; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STAUROSPORINE; SUNITINIB;

EID: 84873056956     PISSN: 13569597     EISSN: 13652443     Source Type: Journal    
DOI: 10.1111/gtc.12022     Document Type: Article
Times cited : (179)

References (57)
  • 2
    • 77955530763 scopus 로고    scopus 로고
    • SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
    • Ahmed, A.A., Lu, Z., Jennings, N.B., et al. (2010) SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18, 109-121.
    • (2010) Cancer Cell , vol.18 , pp. 109-121
    • Ahmed, A.A.1    Lu, Z.2    Jennings, N.B.3
  • 4
    • 0037392942 scopus 로고    scopus 로고
    • The specificities of protein kinase inhibitors: an update
    • Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. (2003) The specificities of protein kinase inhibitors: an update. Biochem J. 371, 199-204.
    • (2003) Biochem J. , vol.371 , pp. 199-204
    • Bain, J.1    McLauchlan, H.2    Elliott, M.3    Cohen, P.4
  • 6
    • 0036857484 scopus 로고    scopus 로고
    • A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
    • Bankston, D., Dumas, J., Natero, R., Riedl, B., Monahan, M.-K. & Sibley, R. (2002) A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer. Org. Proc. Res. Dev. 6, 777-781.
    • (2002) Org. Proc. Res. Dev. , vol.6 , pp. 777-781
    • Bankston, D.1    Dumas, J.2    Natero, R.3    Riedl, B.4    Monahan, M.-K.5    Sibley, R.6
  • 7
    • 34948875686 scopus 로고    scopus 로고
    • Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
    • Bantscheff, M., Eberhard, D., Abraham, Y., et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044.
    • (2007) Nat. Biotechnol. , vol.25 , pp. 1035-1044
    • Bantscheff, M.1    Eberhard, D.2    Abraham, Y.3
  • 10
    • 76649094893 scopus 로고    scopus 로고
    • Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress
    • Chintalgattu, V., Ai, D., Langley, R.R., et al. (2010) Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472-484.
    • (2010) J. Clin. Invest. , vol.120 , pp. 472-484
    • Chintalgattu, V.1    Ai, D.2    Langley, R.R.3
  • 11
    • 36849023013 scopus 로고    scopus 로고
    • Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    • Chu, T.F., Rupnick, M.A., Kerkela, R., et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
    • (2007) Lancet , vol.370 , pp. 2011-2019
    • Chu, T.F.1    Rupnick, M.A.2    Kerkela, R.3
  • 13
    • 0043210670 scopus 로고    scopus 로고
    • FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets
    • Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G. & Pazdur, R. (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8, 303-306.
    • (2003) Oncologist , vol.8 , pp. 303-306
    • Cohen, M.H.1    Williams, G.A.2    Sridhara, R.3    Chen, G.4    Pazdur, R.5
  • 14
    • 0034797512 scopus 로고    scopus 로고
    • The role of protein phosphorylation in human health and disease The Sir Hans Krebs Medal Lecture
    • Cohen, P. (2001) The role of protein phosphorylation in human health and disease The Sir Hans Krebs Medal Lecture. Eur. J. Biochem. 268, 5001-5010.
    • (2001) Eur. J. Biochem. , vol.268 , pp. 5001-5010
    • Cohen, P.1
  • 15
    • 0036527429 scopus 로고    scopus 로고
    • Protein kinases-the major drug targets of the twenty-first century?
    • Cohen, P. (2002) Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug. Discov. 1, 309-315.
    • (2002) Nat. Rev. Drug. Discov. , vol.1 , pp. 309-315
    • Cohen, P.1
  • 17
    • 0034306450 scopus 로고    scopus 로고
    • Specificity and mechanism of action of some commonly used protein kinase inhibitors
    • Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105.
    • (2000) Biochem. J. , vol.351 , pp. 95-105
    • Davies, S.P.1    Reddy, H.2    Caivano, M.3    Cohen, P.4
  • 19
    • 78650334298 scopus 로고    scopus 로고
    • Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo
    • Ding, P., Huang, J., Battiprolu, P.K., Hill, J.A., Kamm, K.E. & Stull, J.T. (2010) Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. J. Biol. Chem. 285, 40819-40829.
    • (2010) J. Biol. Chem. , vol.285 , pp. 40819-40829
    • Ding, P.1    Huang, J.2    Battiprolu, P.K.3    Hill, J.A.4    Kamm, K.E.5    Stull, J.T.6
  • 20
    • 19744365702 scopus 로고    scopus 로고
    • A small molecule-kinase interaction map for clinical kinase inhibitors
    • Fabian, M.A., Biggs, W.H. III, Treiber, D.K., et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
    • (2005) Nat. Biotechnol. , vol.23 , pp. 329-336
    • Fabian, M.A.1    Biggs III, W.H.2    Treiber, D.K.3
  • 22
    • 79551610758 scopus 로고    scopus 로고
    • Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
    • Force, T. & Kolaja, K.L. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-126.
    • (2011) Nat. Rev. Drug Discov. , vol.10 , pp. 111-126
    • Force, T.1    Kolaja, K.L.2
  • 23
    • 60849113175 scopus 로고    scopus 로고
    • KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
    • Gajiwala, K.S., Wu, J.C., Christensen, J., et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl Acad. Sci. USA 106, 1542-1547.
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , pp. 1542-1547
    • Gajiwala, K.S.1    Wu, J.C.2    Christensen, J.3
  • 24
    • 33947423448 scopus 로고    scopus 로고
    • Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
    • Goodman, V.L., Rock, E.P., Dagher, R., et al. (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373.
    • (2007) Clin. Cancer Res. , vol.13 , pp. 1367-1373
    • Goodman, V.L.1    Rock, E.P.2    Dagher, R.3
  • 25
    • 77950042300 scopus 로고    scopus 로고
    • The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
    • Hasinoff, B.B. (2010) The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244, 190-195.
    • (2010) Toxicol. Appl. Pharmacol. , vol.244 , pp. 190-195
    • Hasinoff, B.B.1
  • 26
    • 0037106377 scopus 로고    scopus 로고
    • Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
    • Herbst, R.S., Maddox, A.M., Rothenberg, M.L., Small, E.J., Rubin, E.H., Baselga, J., Rojo, F., Hong, W.K., Swaisland, H., Averbuch, S.D., Ochs, J. & LoRusso, P.M. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20, 3815-3825.
    • (2002) J. Clin. Oncol. , vol.20 , pp. 3815-3825
    • Herbst, R.S.1    Maddox, A.M.2    Rothenberg, M.L.3    Small, E.J.4    Rubin, E.H.5    Baselga, J.6    Rojo, F.7    Hong, W.K.8    Swaisland, H.9    Averbuch, S.D.10    Ochs, J.11    LoRusso, P.M.12
  • 27
    • 65249087328 scopus 로고    scopus 로고
    • A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
    • Houk, B.E., Bello, C.L., Kang, D. & Amantea, M. (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506.
    • (2009) Clin. Cancer Res. , vol.15 , pp. 2497-2506
    • Houk, B.E.1    Bello, C.L.2    Kang, D.3    Amantea, M.4
  • 28
    • 79955752557 scopus 로고    scopus 로고
    • Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques
    • Hurtado, B., Munoz, X., Recarte-Pelz, P., Garcia, N., Luque, A., Krupinski, J., Sala, N. & Garcia de Frutos, P. (2011) Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques. Thromb. Haemost. 105, 873-882.
    • (2011) Thromb. Haemost. , vol.105 , pp. 873-882
    • Hurtado, B.1    Munoz, X.2    Recarte-Pelz, P.3    Garcia, N.4    Luque, A.5    Krupinski, J.6    Sala, N.7    Garcia de Frutos, P.8
  • 30
    • 70349449239 scopus 로고    scopus 로고
    • Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators
    • Imamura, H., Nhat, K.P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai, T. & Noji, H. (2009) Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc. Natl Acad. Sci. USA 106, 15651-15656.
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , pp. 15651-15656
    • Imamura, H.1    Nhat, K.P.2    Togawa, H.3    Saito, K.4    Iino, R.5    Kato-Yamada, Y.6    Nagai, T.7    Noji, H.8
  • 31
    • 33745086350 scopus 로고    scopus 로고
    • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    • Kantarjian, H., Giles, F., Wunderle, L., et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551.
    • (2006) N. Engl. J. Med. , vol.354 , pp. 2542-2551
    • Kantarjian, H.1    Giles, F.2    Wunderle, L.3
  • 32
    • 38049018155 scopus 로고    scopus 로고
    • A quantitative analysis of kinase inhibitor selectivity
    • Karaman, M.W., Herrgard, S., Treiber, D.K., et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132.
    • (2008) Nat. Biotechnol. , vol.26 , pp. 127-132
    • Karaman, M.W.1    Herrgard, S.2    Treiber, D.K.3
  • 34
    • 39549099724 scopus 로고    scopus 로고
    • Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase
    • Kinoshita, T., Miyano, N., Nakai, R., Yokota, K., Ishiguro, H. & Tada, T. (2008) Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase. Protein Expr. Purif. 58, 318-324.
    • (2008) Protein Expr. Purif. , vol.58 , pp. 318-324
    • Kinoshita, T.1    Miyano, N.2    Nakai, R.3    Yokota, K.4    Ishiguro, H.5    Tada, T.6
  • 35
    • 84855221082 scopus 로고    scopus 로고
    • Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase
    • Kitagawa, D., Gouda, M., Kirii, Y., Sugiyama, N., Ishihama, Y., Fujii, I., Narumi, Y., Akita, K. & Yokota, K. (2012) Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. J. Biochem. 151, 47-55.
    • (2012) J. Biochem. , vol.151 , pp. 47-55
    • Kitagawa, D.1    Gouda, M.2    Kirii, Y.3    Sugiyama, N.4    Ishihama, Y.5    Fujii, I.6    Narumi, Y.7    Akita, K.8    Yokota, K.9
  • 36
    • 24944497371 scopus 로고    scopus 로고
    • Features of selective kinase inhibitors
    • Knight, Z.A. & Shokat, K.M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
    • (2005) Chem. Biol. , vol.12 , pp. 621-637
    • Knight, Z.A.1    Shokat, K.M.2
  • 38
    • 19944428353 scopus 로고    scopus 로고
    • Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
    • Lombardo, L.J., Lee, F.Y., Chen, P., et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
    • (2004) J. Med. Chem. , vol.47 , pp. 6658-6661
    • Lombardo, L.J.1    Lee, F.Y.2    Chen, P.3
  • 42
    • 33846821872 scopus 로고    scopus 로고
    • Targeted therapy for metastatic renal cell carcinoma
    • Motzer, R.J. & Bukowski, R.M. (2006) Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 5601-5608
    • Motzer, R.J.1    Bukowski, R.M.2
  • 43
    • 34548744667 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    • Piccaluga, P.P., Paolini, S. & Martinelli, G. (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110, 1178-1186.
    • (2007) Cancer , vol.110 , pp. 1178-1186
    • Piccaluga, P.P.1    Paolini, S.2    Martinelli, G.3
  • 44
    • 55249102194 scopus 로고    scopus 로고
    • Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases
    • Quintas-Cardama, A. & Cortes, J. (2008) Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 4, 611-621.
    • (2008) Future Oncol. , vol.4 , pp. 611-621
    • Quintas-Cardama, A.1    Cortes, J.2
  • 45
    • 33846440150 scopus 로고    scopus 로고
    • Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
    • Rock, E.P., Goodman, V., Jiang, J.X., Mahjoob, K., Verbois, S.L., Morse, D., Dagher, R., Justice, R. & Pazdur, R. (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12, 107-113.
    • (2007) Oncologist , vol.12 , pp. 107-113
    • Rock, E.P.1    Goodman, V.2    Jiang, J.X.3    Mahjoob, K.4    Verbois, S.L.5    Morse, D.6    Dagher, R.7    Justice, R.8    Pazdur, R.9
  • 46
    • 84901290217 scopus 로고    scopus 로고
    • FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2
    • Ryan, Q., Ibrahim, A., Cohen, M.H., Johnson, J., Ko, C.W., Sridhara, R., Justice, R. & Pazdur, R. (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13, 1114-1119.
    • (2008) Oncologist , vol.13 , pp. 1114-1119
    • Ryan, Q.1    Ibrahim, A.2    Cohen, M.H.3    Johnson, J.4    Ko, C.W.5    Sridhara, R.6    Justice, R.7    Pazdur, R.8
  • 48
    • 0037468875 scopus 로고    scopus 로고
    • Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
    • Sun, L., Liang, C., Shirazian, S., et al. (2003) Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2, 4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116-1119.
    • (2003) J. Med. Chem. , vol.46 , pp. 1116-1119
    • Sun, L.1    Liang, C.2    Shirazian, S.3
  • 49
    • 4143149763 scopus 로고    scopus 로고
    • Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
    • Tan, A.R., Yang, X., Hewitt, S.M., et al. (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 22, 3080-3090.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 3080-3090
    • Tan, A.R.1    Yang, X.2    Hewitt, S.M.3
  • 50
    • 49549105363 scopus 로고    scopus 로고
    • Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis
    • Thirunavukkarasu, M., Addya, S., Juhasz, B., Pant, R., Zhan, L., Surrey, S., Maulik, G., Menon, V.P. & Maulik, N. (2008) Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J. Cell Mol. Med. 12, 1284-1302.
    • (2008) J. Cell Mol. Med. , vol.12 , pp. 1284-1302
    • Thirunavukkarasu, M.1    Addya, S.2    Juhasz, B.3    Pant, R.4    Zhan, L.5    Surrey, S.6    Maulik, G.7    Menon, V.P.8    Maulik, N.9
  • 53
    • 35348868577 scopus 로고    scopus 로고
    • Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
    • White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M.F., Lynch, K., To, L.B. & Hughes, T. (2007) Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J. Clin. Oncol. 25, 4445-4451.
    • (2007) J. Clin. Oncol. , vol.25 , pp. 4445-4451
    • White, D.1    Saunders, V.2    Grigg, A.3    Arthur, C.4    Filshie, R.5    Leahy, M.F.6    Lynch, K.7    To, L.B.8    Hughes, T.9
  • 56
    • 55949114398 scopus 로고    scopus 로고
    • AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice
    • Zhang, P., Hu, X., Xu, X., Fassett, J., Zhu, G., Viollet, B., Xu, W., Wiczer, B., Bernlohr, D.A., Bache, R.J. & Chen, Y. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52, 918-924.
    • (2008) Hypertension , vol.52 , pp. 918-924
    • Zhang, P.1    Hu, X.2    Xu, X.3    Fassett, J.4    Zhu, G.5    Viollet, B.6    Xu, W.7    Wiczer, B.8    Bernlohr, D.A.9    Bache, R.J.10    Chen, Y.11
  • 57
    • 68449098174 scopus 로고    scopus 로고
    • Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors
    • Zsila, F., Fitos, I., Bencze, G., Keri, G. & Orfi, L. (2009) Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr. Med. Chem. 16, 1964-1977.
    • (2009) Curr. Med. Chem. , vol.16 , pp. 1964-1977
    • Zsila, F.1    Fitos, I.2    Bencze, G.3    Keri, G.4    Orfi, L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.